Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Omega Therapeutics, Inc. (OMGA : NSDQ)
 
 • Company Description   
Omega Therapeutics Inc. is a development-stage biotechnology company. Its OMEGA Epigenomic Programming(TM) platform harness the power of epigenetics to develop a new class of DNA-sequence-targeting, mRNA-encoded programmable epigenetic medicines. Omega Therapeutics Inc. is based in CAMBRIDGE, Mass.

Number of Employees: 80

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.71 Daily Weekly Monthly
20 Day Moving Average: 171,194 shares
Shares Outstanding: 47.85 (millions)
Market Capitalization: $129.67 (millions)
Beta:
52 Week High: $31.41
52 Week Low: $2.49
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -40.31% -32.78%
12 Week -75.74% -73.33%
Year To Date -76.08% -70.02%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
20 ACORN PARK DRIVE
-
CAMBRIDGE,MA 02140
USA
ph: 617-949-4360
fax: -
argotomega@argotpartners.com http://www.omegatherapeutics.com
 
 • General Corporate Information   
Officers
Mahesh Karande - President; Chief Executive Officer and Director
Noubar B. Afeyan - Chairman of the Board of Directors
Roger Sawhney - Chief Financial Officer
Thomas McCauley - Chief Scientific Officer
Yan Moore - Chief Medical Officer

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 68217N105
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 09/09/22
Share - Related Items
Shares Outstanding: 47.85
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $129.67 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.54 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.17 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 09/09/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.72
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 4.55%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 86.11%
ROE
03/31/22 - -58.81
12/31/21 - -83.15
09/30/21 - -
ROA
03/31/22 - -36.39
12/31/21 - -45.02
09/30/21 - -
Current Ratio
03/31/22 - 15.23
12/31/21 - 19.13
09/30/21 - 16.69
Quick Ratio
03/31/22 - 15.23
12/31/21 - 19.13
09/30/21 - 16.69
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -18,193.20
12/31/21 - -47,416.67
09/30/21 - -
Book Value
03/31/22 - 3.79
12/31/21 - 4.20
09/30/21 - 4.61
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.11
12/31/21 - 0.10
09/30/21 - 0.03
Debt-to-Capital
03/31/22 - 9.88
12/31/21 - 9.01
09/30/21 - 3.29
 

Powered by Zacks Investment Research ©